Ingmar Hoerr

Ingmar Hoerr is the co-founder of CureVac, a biopharmaceutical company that specializes in mRNA technology for vaccine development. He has been instrumental in the company's evolution from focusing on infectious diseases to concentrating on cancer immunotherapies. Recently, he was in the news following the announcement of CureVac's acquisition by BioNTech, which he views as a positive development for the European biotech landscape, believing it will enhance innovation in mRNA technology.